Open access • Journal Article • DOI:10.1111/ENE.13322

European consensus on the concepts and measurement of the pathophysiological neuromuscular responses to passive muscle stretch — Source link

J. van den Noort, Lynn Bar-On, Lynn Bar-On, Erwin Aertbeliën ...+35 more authors

Institutions: VU University Medical Center, Katholieke Universiteit Leuven, Norwegian University of Science and Technology, Karolinska University Hospital ...+10 more institutions

Published on: 01 Jul 2017 - European Journal of Neurology (Wiley)

Topics: Hypertonia

Full title: European consensus on the concepts and measurement of the pathophysiological neuromuscular responses to passive muscle stretch

Running title: consensus on pathophysiological neuromuscular responses to passive muscle stretch

Josien C. van den Noort*[1,2]; Lynn Bar-On*[1,3,4]; Erwin Aertbeliën[5]; Martin Bonikowski[6]; Siri M. Braendvik[7,8]; Eva W. Broström[9]; Annemieke I. Buizer[1]; Jane H. Burridge[10]; Anja van Campenhout[11]; Bernard Dan[12]; Judith F. Fleuren[13]; Sebastian Grunt[14]; Florian Heinen[15]; Herwin L. Horemans[16]; Christine Jansen[17,18]; Andreas Kranzl[19]; Britta K. Krautwurst[20]; Marjolein van der Krogt[1,2]; Sergio Lerma Lara[21,22]; Cecilia M. Lidbeck[9]; Jean-Pierre Lin[23]; Ignatio Martinez[21]; Carel Meskers[1,2]; Dimitris Metaxiotis[24]; Guy Molenaers[11]; Dimitrios A. Patikas[25]; Olivier Rémy-Néris[26]; Karin Roeleveld[7]; Adam P. Shortland[27]; Janine Sikkens[28]; Lizeth Sloot[1,2]; R. Jeroen Vermeulen[29]; Christine Wimmer[17]; A. Sebastian Schröder[18]; Simon Schless[3,4]; Jules G. Becher[1]; Kaat Desloovere[3,4]; Jaap Harlaar[1,2]

* *Shared first authorship*

[1] *VU University Medical Center, Department of Rehabilitation Medicine, Amsterdam, The Netherlands*

[2] *Amsterdam Movement Sciences, The Netherlands*

[3] *University Hospital Pellenberg, Clinical Motion Analysis Laboratory, Leuven, Belgium*

[4] *KU Leuven Department of Rehabilitation Sciences, Leuven, Belgium*

[5] *KU Leuven Department of Mechanical Engineering, Leuven, Belgium*

[6] *Mazovian Neuropsychiatry Center, Limited Liability Company, Neuro - Rehabilitation Department, Movement Analysis Lab, Zagórze n. Warsaw, Poland, 05-462 Wiązowna*

[7] *Norwegian University of Science and Technology (NTNU), Department of Neuroscience, Trondheim, Norway*

[8] *Clinical sevices, St. Olavs University Hospital, Trondheim, Norway*

[9] *Department of Women's and Children's Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden*

[10] *Faculty of Health Sciences, University of Southampton, Southampton, United Kingdom*

[11] *Department of Orthopaedic Surgery, University Hospital Leuven and Department of Development and regeneration, KULeuven, Belgium*

[12] *Université Libre de Bruxelles (ULB), Brussels, Belgium and Inkendaal Rehabilitation Hospital, Velzenbeek, Belgium*

[13] *Roessingh Research and Development, Enschede, The Netherlands*

[14] *Division of Neuropaediatrics, Development and Rehabilitation, University Children's Hospital Bern, Inselspital, Bern University Hospital, University of Bern, Switzerland*

[15] *Department of Pediatric Neurology and Developmental Medicine, Integrated Social Pediatric Center, Ludwig-Maximilians-University, Munich, Germany*

[16] *Department of Rehabilitation Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands*

[17] *Department of Physiotherapy and Department of Paediatric Neurology and Rehabilitation, Schön Clinic Vogtareuth, Vogtareuth, Germany*

[18] *Department of Paediatric Neurology and Developmental Medicine, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University Munich, Germany*

[19] *Orthopaedic Hospital Speising, Laboratory of gait and human movement analysis, Vienna, Austria*

[20] *Heidelberg University Hospital, Centre for Orthopedics and Trauma Surgery, Heidelberg, Germany*

[21] *Laboratorio de Análisis del Movimiento, Hospital Infantil Universitario Niño Jesús, Madrid, Spain*

[22] *Physical Therapy Dept. Centro Superior de Estudios Universitarios de La Salle. Universidad Autónoma de Madrid, Spain*

[23] *Complex Motor Disorders Service, Evelina Children's Hospital, London, United Kingdom*

[24] *Department of Orthopaedics, Papageorgiou Hospital and ELEPAP, Thessaloniki, Greece*

[25] *Faculty of Physical Education and Sport Sciences, Aristotle, University of Thessaloniki, Thessaloniki, Greece*

[26] *CHRU de Brest, Hôpital Morvan, Service de Médecine Physique et de Réadaptation, Brest, France.*

[27] *One Small Step Gait Analysis Laboratory, Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom*

[28] *VU University Medical Center, Pontes Medical, Department of Physical and Medical Technology, Amsterdam, the Netherlands*

[29] *Department of Neurology, Maastricht University medical center, Maastricht, The Netherlands*

Corresponding Author: Josien van den Noort, PhD; VU University Medical Center, Department of Rehabilitation Medicine; PO Box 7057, 1007 MB Amsterdam, The Netherlands; Tel.: +31 20 444 3192; Fax: +31 20 444 0787; e-mail: j.vandennoort@vumc.nl

The total number of words of the manuscript (introduction-conclusion): 5050

The number of words of the abstract: 250; Figures: 1; Tables: 5; Appendix: 1

Keywords: physical examination, hyper-resistance, neurological disorders, framework, muscle, spasticity

Abstract

Background: To support clinical decision-making in central neurological disorders, physical examination is used to assess responses to passive muscle stretch. However, what exactly is being assessed is expressed and interpreted in different ways. A clear diagnostic framework is lacking. Therefore, the aim was to arrive at unambiguous terminology about the concepts and measurement around pathophysiological neuromuscular response to passive muscle stretch.

Methods: During two consensus meetings, 37 experts from 12 European countries filled online questionnaires based on a Delphi approach, followed by plenary discussion after rounds. Consensus was reached when agreement ≥75%.

Results: The term *hyper-resistance* should be used to describe the phenomenon of impaired neuromuscular response during passive stretch, instead of e.g. 'spasticity' or 'hypertonia'. From there, it is essential to distinguish *non-neural* (tissue-related) from *neural* (central nervous system related) contributions to hyper-resistance. Tissue contributions are elasticity, viscosity and muscle shortening. Neural contributions are velocity dependent *stretch hyperreflexia* and non-velocity dependent *involuntary background activation*. The term 'spasticity' should only be used next to stretch hyperreflexia, and 'stiffness' next to passive tissue contributions. When joint angle, moment and electromyography are recorded, components of hyper-resistance within the framework can be quantitatively assessed.

Conclusions: A conceptual framework of pathophysiological responses to passive muscle stretch was defined. This framework can be used in clinical assessment of hyper-resistance and will improve communication between clinicians. Components within the framework are defined by objective parameters from instrumented assessment. These parameters need experimental validation in order to develop treatment algorithms based on aetiology of the clinical phenomena.

Introduction

Impaired motor control is a consequence of most central nervous system movement disorders such as cerebral palsy (CP), stroke (CVA), spinal cord injury (SCI) or multiple sclerosis (MS). A common physical examination includes assessment of the resistance to passive muscle elongation. This examination is used to make judgments on the degree and nature of muscle hyper-resistance, to determine aetiology at the level of the muscular tissue and/or motor control, and to infer consequences for overall motor performance in functional tasks. It is considered important to a meaningful description of the clinical status of the patient and essential to inform decisions on the treatment options [1].

Although such physical examination is in widespread clinical use and yields clinically essential information, the concept of what is being assessed cannot be unambiguously phrased. This is expressed in the variety of typically used nomenclature for what is being assessed, e.g. hyper-resistance, spasticity, hypertonia, stiffness, (dynamic) contracture, or hypo-extensibility [2-11]. This is accompanied by a variety of interpretations, i.e. how these findings relate to presumed underlying pathophysiology. Therefore, in clinical practice, the concepts of pathophysiological neuromuscular response to passive muscle stretch must be considered implicit rather than explicit. The lack of a clear diagnostic conceptual framework obstructs effective communication between clinicians, and impedes construction of reliable treatment algorithms. Moreover, quantifying results of an assessment requires grading based on measurement instruments that, by definition, must rely on unambiguous conceptualization.

All in all, this diversity in clinical practices calls for a consensus on the conceptualization, interpretation and measurement of the pathophysiological neuromuscular responses to

imposed passive elongation, to fully exploit the potential of this diagnostic test in the context of treating patients with neurological diseases.

General physiological concepts

The aetiology of increased resistance to passive muscle stretch has both neurological and non-neurological components. The primary neurological component is generally accepted as being caused by supraspinal disregulation (disinhibition) of the spinal reflex loop, as a direct result of the neurological insult [12, 13]. This reflex loop evokes a *stretch reflex*, an essential mechanism of motor control that occurs when a muscle is lengthened rapidly and/or forcefully. Normally, stretch reflex activity is low when a muscle is passively lengthened. In the case of disinhibition due to a neurological insult, the stretch reflex is more readily elicited. This hyperactive reflex causes muscle contraction and therefore an opposing force to passive elongation. In fact, the complete pathophysiology of neural contributors is much more complex than this simplified description, as several mechanisms can be identified that give rise to involuntary muscle contractions resulting in increased resistance of muscles to their elongation. These mechanisms are referred to as excess, or positive motor symptoms, of the neurological disorder, as opposed to the deficit, or negative symptoms, that reflect the impairment to activate a muscle purposefully.

The non-neurological component of muscle hyper-resistance consists of secondary impairments that are thought to occur as a result of muscular adaptations to the neural dysregulation. For instance, muscles might shorten (muscle contractures) or stiffen due to intrinsic changes in the muscle tissue. In children these effects might be amplified as result of maladaptation to growth.

Definitions

Pathophysiological responses to passive muscle elongation have been defined and named. The use of the term '*spasticity'* has been used to refer to either an aetiology at spinal level or to a clinical expression at a joint level. Such wide usage of the term has led to its definition being subject to debate for a long time [6, 7]. One of the commonly used definitions of spasticity was provided by Lance in 1980: "*a motor disorder characterized by a velocity dependent increase in tonic stretch reflexes (muscle tone) with exaggerated tendon jerks, resulting from hyper excitability of the stretch reflex, as one component of the upper motor neurone syndrome*" [3]. Clearly, Lance refers to the pathophysiological mechanisms. Sanger et al. (NIH task force, 2003) stayed closer to the clinical phenomena and defined spasticity as "*hypertonia in which one or both of the following signs are present: 1) resistance to externally imposed movement increases with increasing speed of stretch and varies with the direction of joint movement, and/or 2) resistance to externally imposed movement rises rapidly above a threshold speed or joint angle*" [4]. Other features of neuromuscular impairments were defined by them as well, all under the umbrella term '*hypertonia'*. The definitions by Lance and by Sanger et al. are mutually compatible.

In 2005, the SPASM consortium introduced a new definition of spasticity using a motor control approach: "*disordered sensori-motor control, resulting from an upper motor neurone lesion, presenting as intermittent or sustained involuntary activation of muscles* " [8, 9]. This definition includes the entire range of signs and symptoms that are collectively described as excess features, and not exclusively the hyperactive stretch reflex.

Common clinical tests

Several physical examination tests have been constructed to assess spasticity or resistance in clinical practice, such as the (Modified) Ashworth Scale (MAS), the Tardieu Scale and the

Spasticity Test (SPAT, a simplification of the Tardieu Scale) [1, 14-25]. In these tests, passive muscle elongations are imposed at one or more velocities by the examiner. Perceived resistance during slow passive elongation is assumed to be related only to non-neural (changed mechanical response of the neuromuscular complex, i.e. stiffness (elasticity) and viscosity) components. In muscles with spasticity, high stretch velocities may additionally cause increased resistance and/or a catch, i.e. a stop in the movement due to the hyperactive stretch reflex [15, 26]. In contrast to the Tardieu Scale and the SPAT, the MAS does not use multiple velocities, and scores a single value, thereby not discriminating between neural and non-neural contributions [21].

Although such physical examinations are commonly used in clinical practice, the resistance perceived by the examiner is difficult to relate to either a neural or non-neural origin [7, 27]. Moreover, the velocity of stretch as well as the level of activity of the muscle are uncontrolled [7, 16, 19, 23, 28]. Finally, the outcome of these tests is a numeric value scored by the examiner and based on subjective feeling and joint angle measurement with goniometry. Standardisation, reliability, sensitivity, quantification, and objectivity are lacking in these tests.

Instrumented tests

To unravel the neural and non-neural contributions to hyper-resistance during passive muscle elongation, instrumented assessments have been developed in several research settings [7, 16, 22, 24, 26-30]. These measurements employ electrophysiological signals (electromyography (EMG)) to assess the stretch reflex, in combination with joint movement (kinematics) and applied torques (net joint moment). In this way the resistance to muscle elongation can be objectified and the neural and non-neural aspects specifically discriminated, in order to arrive

194 at the correct treatment option, based on aetiology [28, 29]. Next to assessment of the stretch
195 reflex, the measurement of the Hoffman-reflex, using submaximal electric stimulation of the
196 nerve, is used to study the excitability of the Ia afferents [25, 31, 32].

197 Although there have been multiple efforts to arrive at clear concepts, and instruments are
198 developed to express objectivity, there is yet no unambiguous and generally accepted
199 conceptual frame work that incorporates a meaningful decomposition of perceived
200 phenomena with associated operationalization. Therefore, two consensus meetings were
201 organized with the aim (1) to arrive at unambiguous terminology about the concepts of, and
202 phenomena around, pathophysiological neuromuscular response to passive muscle stretch and
203 (2) to define requirements from a clinical perspective that enable the development of
204 instruments to quantitatively measure the defined concepts in clinical practice.

Methods

Thirty-seven participants from twelve European countries joined two consensus meetings, on 22-23 May 2014 in Amsterdam, the Netherlands and a follow-up meeting on 8 September 2015 in Heidelberg, Germany. Participants, from, but not restricted to, the network of the organizers (JN, JH, JB, LB, KD), were invited for the meetings based on their publications related to this field, and their experience in either treating or assessing spasticity in a clinical or research setting. Prior to the first meeting, participants were asked to fill in an online questionnaire (NETQ Internet Surveys, NetQuestionnaires Nederland BV, Utrecht, the Netherlands) about their background and experience with clinical spasticity assessment. Characteristics of the participants are presented in Table 1. During the meetings, a modified Delphi approach [33] was used to arrive at consensus about (1) terminology about the concepts of, and phenomena around, response to passive muscle stretch and (2) boundary conditions from clinical perspective to enable development of instruments to quantitatively measure the defined concepts in clinical practice.

Part 1

At the first meeting (31 participants), a schematic overview (Figure 1A) was presented to the participants. This overview was developed by the organizers of the consensus meetings (JH, JB, KD, LB, JN) based on careful review of the literature (as described in the Introduction) and their own experience in the field, with the aim to initiate the discussion on concepts and (new) terminology. Using this overview, a discussion was initiated on the terminology, concepts and phenomena around pathophysiological neuromuscular responses to passive muscle stretch. Thereafter, a Delphi questionnaire, consisting of 12 statements using a Likert

scale (i.e. strongly disagree, disagree, neutral, agree, strongly agree) (Table 2) was anonymously filled in by the participants (NETQ Internet Surveys, NetQuestionnaires Nederland BV, Utrecht, the Netherlands). The included domains were: terminology on the concepts, non-neural and neural contributions, and passive versus active impairment.

Subsequently, results of this first round were collated, presented to participants and discussed plenary. Consensus was reached when agreement was 75% or higher. Unclear questions from round 1 were rephrased and a second Delphi round of 8 statements was conducted (Table 3) on the same domains. Next, results of the second round were presented to the participants and discussed plenary to further reach consensus on those statements that were unclear or had limited agreement.

During the second meeting (26 participants), a summary of the results of the two Delphi rounds and the discussions of the first meeting was presented, followed by a plenary discussion for final agreement on conceptualization and terminology.

Part 2

To determine the requirements for instrumented measurement of the defined concepts in clinical and research practice, designs and data from previous instrumented setups developed in research settings were presented to the participants at the first meeting (such as described in the Introduction section of this paper). Subsequently, a Delphi round on concepts of measurement was carried out which included 75 questions or statements (Table 4) related to the following domains: pathology, muscles, in- and exclusion criteria, test time allowance, patient position, movement profile, theoretical importance of signals and sensors, practical feasibility of signals and sensors, feedback, outcome parameters, report, and training.

Questions were multiple choice or used the Likert scale. Results of the questionnaire were discussed plenary.

During the second meeting, a second Delphi round about concepts of measurements was conducted which included 18 rephrased statements that were unclear to the participants or had not reached consensus in round 1. The included domains were: protocol, feedback and report.

As instrumented measurement of spasticity in clinical settings is still fairly innovative, the aim of part 2 was not to reach full consensus on all questions but to get insight into important aspects for future development of a clinically-applicable instrumented spasticity assessment.

Results

Participant characteristics

Twenty-seven participants completed the online questionnaire about background, profession and experience with clinical spasticity assessment. Most responders were clinicians (86%) as well as researchers (86%), 71% of the responders clinically assessed patients with spasticity and 48% carried out clinical treatment of spasticity. Years of experience in assessing or treating spasticity ranged between 1 and 30 years, with a mean of 13 years and median of 15 years. The (modified) Tardieu scale was the most commonly used clinical test (57%) followed by the (modified) Ashworth scale (53%). Tests were mostly performed by physiotherapists (76%) or medical doctors (71%), most of the time before and after treatment (67% always before and after) and sometimes during consultations (62%). Most responders were unsatisfied with the current clinical tests (47%) or were neutral (33%). Of the participants using a form of instrumented assessment (81%), 24% were unsatisfied and 38% neutral.

Part 1: Conceptualization and terminology

Twenty-eight participants completed the first, and 30 participants completed the second Delphi round on the conceptualization of the pathophysiological neuromuscular responses to passive muscle stretch (Table 2 and 3).

In the initial plenary discussion following the presentation of the schematic overview (Figure 1A), the following was discussed: 1. *Increased resistance perceived by an examiner during physical examination*, i.e. passive muscle stretch, is, apart from the term spasticity, often termed *hypertonia*, which implies that the resistance results from involuntary muscle activation. 2. However, since hypertonia may also exist at rest (without muscle stretch), it

may not be equated to the resistance perceived during stretch. Therefore, the term *hyper-resistance* was suggested. 3. Although still the mostly commonly used term in clinical practice, it was also suggested to be careful with the term *spasticity*, since it may not cover all aspects of the perceived resistance.

During the first Delphi round (Table 2), it was concluded that the term 'hyper-resistance' is preferred over the terms 'hypertonia' and 'spasticity' to describe the phenomenon of impaired neuromuscular response during passive stretch. Hyper-resistance is therefore defined as increased resistance perceived during passive muscle stretch.

It was agreed that it is essential to distinguish non-neural (tissue-related) from neural (CNS related) contributions to hyper-resistance. It was proposed that the different contributions could be described by three subgroups: muscle tissue properties (non-neural), hyperstretch reflex (neural and induced by motion) and involuntary activation (neural) (Figure 1B). Muscle tissue properties consist of muscle stiffness (elasticity) and viscosity. Participants remarked that joint stiffness and viscosity are not only the result of muscle tissue properties, but are also influenced by the ligaments and surrounding tissue. However, hyper-resistance reflects neuromuscular unit function only when no bony and ligament response is assumed (second Delphi round, Table 3).

During the first Delphi round (Table 2) consensus was reached that it is essential to distinguish hyperstretch reflex and other muscle activity within the neural (CNS related) contributions to hyper-resistance. Clonus and clasp-knife are specific manifestations of the exaggerated stretch reflex. In the discussion prior to the first Delphi round it was suggested that hyper-resistance is the net effect of the agonist and antagonist muscles, and co-contraction might be present during examination. Therefore, co-contraction should be considered as part of the involuntary activation subgroup. In the second Delphi round (Table 3), the majority of the participants agreed that hyper-resistance reflects the neuromuscular unit

function of an agonist muscle group only when no effects of antagonistic muscle(s) (shortening) is assumed.

In the discussion prior to the second Delphi round, three alternatives were proposed for terminology of the two neural contribution subgroups to hyper-resistance, i.e. “hyperstretch reflex” and “involuntary activation” (Figure 1B). In the second Delphi round (Table 3), consensus was reached that the *neural contributions to hyper-resistance* must be distinguished in *“velocity dependent involuntary activation”* and *“non-velocity dependent involuntary activation”*. Also the terms *“stretch hyperreflexia”* and *“involuntary background activation”* were considered to be appropriate as alternative terms to distinguish different neural contributions (Figure 1B) and further used in the final discussions in combination with the terms *“(non-)velocity dependent”* (Figure 1C). Participants showed less preference for the terms “stretch reflex involuntary activation” and “non-stretch reflex involuntary activation”.

In the final discussions of the conceptualization phase (following the two Delphi rounds), the characteristics of subgroups of hyper-resistance were further specified (Figure 1C).

(Muscle) tissue properties (non-neural) contain elasticity, viscosity and shortening. The neural contributions are subdivided into stretch hyperreflexia (velocity dependent) and involuntary background activation (non-velocity dependent). Postural reflexes, non-selective activation, tonic reflexes and fixed background tone are all part of the involuntary background activation.

The word ‘spasticity’ is not part of the conceptual framework, since almost all participants (strongly) agreed that the term ‘spasticity’ should be used with care and only when clearly defined (Table 3). Also, participants agreed that the term refers to involuntary, stretch-velocity induced muscle activity as part of the neural contributions to hyper-resistance (definition according to Lance and Sanger et al. [3, 4]) (Table 2 and 3). Therefore, within the

framework, spasticity refers to velocity dependent stretch hyperreflexia as part of hyper-resistance, and should only be used next to the term 'stretch hyperreflexia'.

Also, the term 'stiffness' is not part of the conceptual framework. It is mechanically defined as the linear relation between joint angle and joint moment (i.e. elasticity), however in practice, the term 'stiffness' is often used in a broader perspective to refer to various (muscle) tissue properties. In this case, it should only be used next to the term (muscle) tissue related contributions to hyper-resistance.

Finally, it was discussed whether passive measurement is representative of the problems occurring during active, functional tasks. Hyper-resistance (ICF body functions and structures level, WHO 2001 [34]) only partly determines any impaired muscle function during performance of activities (ICF activity level) (Table 2). Further research should compare the hyper-resistance measured during passive and active movements.

Part 2: Requirements for instrumented measurement of hyper-resistance

Twenty-eight participants completed the first questionnaire, and 19 participants completed the second questionnaire about concepts of measurement. Outcomes (Tables 4 and 5) showed that an instrumented assessment of hyper-resistance must be applicable to children (>3years) and adults with cerebral palsy, stroke, SCI and MS. The main muscle groups that need to be assessed are (lower limb) medial and lateral gastrocnemius, soleus, rectus femoris, hamstrings (semimembranosus and semitendinosus) and to a lesser extent hip adductors, as well as (upper limb) elbow and wrist flexors. It is required that patients must be in a comfortable position that promotes muscle relaxation during the test.

The test procedure must start from the minimum end of the range of motion (corresponding to the shortest muscle length) to the maximum end of the range of motion (corresponding to the

longest muscle length). The assessment is not applicable to joints with fixed deformities or muscle contractures that limit the range of motion in the direction of movement to less than 10 degrees. At least two different stretch velocities are required (slow and fast), the number of stretches must be kept to a minimum and a rest period is necessary between repetitions. It is important to hold the end of the stretch for a minimum amount of time in order to capture differences in type of catch (e.g. 2-5 sec.). Feedback on the achieved stretch velocity, muscle activity (agonist and antagonist), range of motion in direction of movement and force applied in main direction of movement are essential.

From the first Delphi round (Table 4), requirements for outcome parameters of instrumented assessment concerning neural contributions (either available in a report or in raw data that can be processed post-hoc) are: amount of reflex activity measured by EMG (i.e. mean amplitude over a certain period), timing of EMG activation, duration of EMG activity and increase in EMG amplitude due to velocity and due to position separately. Essential non-neural based parameters are start and end joint angle, joint range of motion (ROM) and angle of catch (AOC) [28], as well as maximal angular velocity. A clinical report of instrumented assessment should contain at least discrete values of the recommended outcome parameters and comparisons of the data with typically developing/healthy subjects, as well as pre- or post-treatment comparisons.

Following on this, in the second Delphi round (Table 5), it was agreed that for a slow stretch, the following five outcome parameters would be sufficient in a report: ROM, maximal angular velocity, average root mean square EMG, stretch reflex threshold (i.e. joint angle at which EMG onset is first detected) and average work. Eighteen percent of the participants also indicated that stiffness (i.e. elasticity: the linear relation between joint angle and joint moment) might be a valuable outcome parameter for a slow stretch. For a fast stretch, six outcome parameters should be included: maximal angular velocity, average root mean square

EMG, stretch reflex threshold, average work, AOC and intensity of catch. As a difference between slow and fast stretch three outcome parameters should be included: difference between ROM and AOC, difference in average root mean square EMG, difference in work.

By these requirements, the three components in the conceptual framework of the pathophysiological neuromuscular responses to passive muscle stretch (muscle tissue properties, stretch hyperreflexia and involuntary background activation) could be linked to instrumented measurement of the joint angle, net joint moment and EMG to quantify the components of hyper-resistance (Figure 1C).

Discussion

A conceptual framework of the pathophysiological neuromuscular responses to passive muscle stretch was defined. This framework enables unambiguous terminology and a clear definition of the contributions to the clinical phenomenon of hyper-resistance that can be used in clinical practice and instrumented assessment. This will optimize communication between clinicians, improve diagnostics and objectify treatment outcomes.

In summary, the participants concluded that the term ‘hyper-resistance’ should be used to describe the phenomenon of the pathophysiological neuromuscular responses to passive muscle stretch, instead of spasticity or hypertonia. Furthermore, it was considered essential to distinguish non-neural (tissue-related) from neural (central nervous system related) contributions to hyper-resistance. Tissue properties consist of elasticity, viscosity and muscle shortening. The neural contributions are two-fold: velocity dependent stretch hyperreflexia and non-velocity dependent involuntary background activation. The term ‘spasticity’ should be used with care, only when clearly defined, next to the term ‘stretch hyperreflexia’. The same holds for the term ‘stiffness’, that should only be used next to tissue related contributions to hyper-resistance.

The components of hyper-resistance in the framework can be quantitatively assessed using instrumented measurement of the joint angle, net joint moment and EMG during slow and fast passive muscle stretch. Instruments like gyroscopes, accelerometers, force sensors and EMG sensors can be used to obtain these signals [16, 26-28, 30]. A list of outcome parameters to be derived from these signals was determined.

Clinical implications

The framework and the related requirements for instrumented assessment as defined by the consensus describe and measure the pathophysiological neuromuscular responses to passive muscle stretch. Some aspects of the defined parameters have already been validated in various patient groups, compared to clinical scores and assessed pre-post treatment [22]. Further experimental validation of the proposed parameters to measure hyper-resistance, could be used to advance treatment algorithms that are based on aetiology of the clinical phenomena. In clinical practice however, physical examination is only one part of the clinical routine, reflecting only some aspects of the 'body functions and structures' level of the ICF , upon which clinicians base their diagnoses and prognoses of treatment plans [34]. As such, clinical decision-making in relevant patient groups is not solely based on passive tests, but also involves clinical gait analyses [35] and assessment of the 'activity' and 'participation' domains of the ICF.

In the online questionnaire filled in prior to the first consensus meeting, 47% of the participants indicated to be unsatisfied with the current clinical tests (Table 1). Furthermore, 24% of the responders were unsatisfied with the currently available instrumented assessments. These findings might be related to experience with the commonly used Ashworth scale which is not standardized, not reliable, not discriminative and poorly related to reflex muscle activity [21]. Dissatisfaction with instrumented assessment might be related to too complex instruments that are not suitable for clinical use (like robotic systems), or too simple measures that are not precise or do not measure multiple parameters (like goniometry) [16]. Also, instrumented measurements can be time consuming which may limit its use in clinical practice. These factors stress the fact that clear terminology on the concepts of the pathophysiological responses is needed, as well as development of instrumented measurement that is meaningful towards these concepts and easily applicable in clinical practice. To further

assess clinical and research applicability, it is essential to formally investigate the clinical feasibility, patient and assessor usability and friendliness of any developed instruments.

Low correlations between clinical scales like the Ashworth and instrumented assessments have been reported [18, 21, 23]. The new framework helps explain these findings, and may lead to recommendations for use of existing clinical scales or development of new scales. Assessment of the sensitivity of parameters, measured with an instrument, to different treatments, might lead to classification of treatments based on the three components of the framework, e.g. botulinum toxin type-A, baclofen and selective dorsal rhizotomy (related to neural contributions) or orthopaedic surgery, casts or splints (related to non-neural contributions) [36].

The defined requirements on instrumented measurement also provide some guidelines for the assessment of patients such as patient position, ROM, muscle stretch velocities and use of outcome parameters needed for clinical decision-making (related to the framework). The posture of the patient influences the muscle length [10, 37], and should therefore be standardized. Some studies also already described standardized postures and movements for some clinical hyper-resistance tests [15, 16, 38, 39]. With regard to stretch velocity and interpretation of outcome parameters, it needs to be realized that in some cases it might be difficult to differentiate the neural and non-neural components of hyper-resistance, for example if a fast velocity cannot be obtained due to altered muscle properties (shortening, elasticity) or high background activation.

It was not the aim of the consensus meeting to develop a new definition of ‘spasticity’ to be used in clinical and research practice. However, agreement was reached that the term ‘spasticity’ should refer to stretch reflex activity, in according to Lance’s and Sanger’s definitions (Tables 2 and 3). More importantly, the consensus stated to use the term ‘spasticity’ with care Avoiding the word ‘spasticity’ may not be easy in clinical practice, as it

464 is still widely used. Therefore, it is advised to only use the term when clearly defined, and
465 next to the term 'stretch hyperreflexia' (Figure 1C).

466

467 *Further directions*

468 Some components in the proposed framework need further clarification. The non-velocity
469 dependent, involuntary background activation that can sometimes be observed during slow
470 passive muscle stretch, might also be influenced by other phenomena [10]. Also, if patients
471 are not able to completely relax during the testing; assist or oppose an imposed movement; or
472 experience pain during the movement, it might be difficult to discriminate this muscular
473 activation from pathological involuntary background activation. Therefore, it should be a
474 future aim to develop methods that can distinguish underlying factors in background muscle
475 activation.

476 Different requirements for detecting the different non-neural and neural contributions to
477 hyper-resistance were proposed. Two stretch velocities were advised (slow and fast).
478 However, it is yet not defined what velocity and movement profile should be applied. In
479 physical examination the movement profile is determined by constraints of human
480 performance of the examiner, as opposed to motorized tests in which a particular movement
481 profile can be imposed [40-43]. However, a motorized test is less feasible in clinical practice
482 and constant velocities do not represent natural movement profiles [44]. To standardize the
483 movement profile in manual testing feedback on achieved stretch velocity, range and direction
484 of movement can be provided. This might be different for each muscle, per age range and
485 patient population, as a consequence of muscle length, initial position, muscle volume and
486 weight of the body segment. For future research it is advised to establish further guidelines on
487 movement velocity, either in ranges or thresholds.

Previous research suggested that reflex activity is both length and velocity dependent [10, 37, 38]. The effect of muscle length might possibly be established using the slow passive movement, taking into account the delay between the trigger and the electrical response and the delay between the electrical and mechanical response of specific muscles [26, 45]. For example, the delay between maximal joint angular velocity and stretch reflex threshold might be an additional valuable outcome parameter in instrumented assessment. Furthermore, as mentioned before, the posture of the patient influences the muscle length [10, 37], and should therefore be standardized.

Clinical research will most certainly benefit from the recommended framework and instrumented assessment. Is ensures the use of similar terminology and standardization in measurement, leading to data comparison and data pooling and, with that, a framework to investigate many clinically relevant research questions. This in turn will support clinicians by providing detailed information on the underlying pathology and effectiveness of treatment.

Further, instrumentation and standardization of performance of passive muscle stretch in clinical practice will enable pre-post intervention comparisons and may optimize precision diagnostics and patient-specific treatment. This requires experimental validation of the proposed outcome parameters obtained from instrumented measured joint angles, joint moments and EMG, which is subject of further study.

Limitations of the study

Since both researchers and non-physicians were invited to participate in the consensus, not all participants personally treat spasticity in daily clinical practice (48% does, Table 1). However, all participants are experienced in either assessing or measuring hyper-resistance in a clinical (71%) or research setting (81%). Furthermore, 86% of the participants were clinicians responsible either for clinical decision-making, executing the physical examinations

513 or working as part of a multi-disciplinary team that treats spasticity. Since the consensus was
514 focussed on concepts of assessment and measurement, the participants very well represent the
515 professionals in the field related to this topic. As we believe that close collaboration between
516 clinicians and (applied) researchers is key to a better understanding of the complex
517 phenomena, and hence better treatment in the future, we consider the heterogenetic
518 composition an asset of the study.
519 The first schematic overview presented was developed by the organizers of the consensus
520 meetings, as were the first round of Delphi questionnaires. This might have introduced bias.
521 However, the aim of the first overview and the first generation of statements (based on careful
522 review of the literature and own experience) was to discuss, to rephrase the statements and to
523 reach consensus. The Delphi method [33] is specifically designed to work in this way.
524
525

Conclusion

A conceptual framework of the pathophysiological neuromuscular responses to passive muscle stretch was defined, based on European consensus meetings with experts in the field. The neutral term hyper-resistance should be used to describe the phenomenon of impaired neuromuscular responses during passive stretch. It is essential to distinguish non-neural from neural contributions to hyper-resistance. This framework can be used to standardize and objectify the clinical assessment of hyper-resistance and will improve communication between clinicians and researchers. Components within the framework are defined by objective parameters that can be derived from instrumented assessment. These parameters need experimental validation after which they can be used as part of the development of treatment algorithms that are based on the aetiology of the clinical phenomena.

539 **Acknowledgements**

540

541 This project was supported by the Phelps Stichting voor Spastici, The Netherlands (grant
542 number 2012026), and by Fonds NutsOhra, The Netherlands (grant number 1301-054), to JN,
543 JS, JB, JH, LB and KD. LB was also supported by the Flamish Research Foundation (FWO),
544 Belgium, grant 12R4215N.

545 The organization of the first consensus meeting in Amsterdam was partly supported by
546 Allergan and by Medtronic. A location for the second consensus meeting was kindly provided
547 by Dr. Sebastian I. Wolf and Dr. Thomas Dreher of Heidelberg University.

548

549 **Figure caption**

550

551 **Figure 1. (A)** Schematic overview to discuss terminology in concepts of and phenomena
552 around pathophysiological neuromuscular response to passive muscle stretch; **(B)** Alternative
553 terms for hyperstretch reflex and involuntary activation as part of hyper-resistance; **(C)** Final
554 conceptual framework of pathophysiological neuromuscular responses to passive muscle
555 stretch.

References

[1]. Boyd RN, Graham HK. Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. *European Journal of Neurology*. 1999 **6:** S23-S35.
[2]. Jethwa A, Mink J, Macarthur C, Knights S, Fehlings T, Fehlings D. Development of the Hypertonia Assessment Tool (HAT): a discriminative tool for hypertonia in children. *Dev Med Child Neurol*. 2010 **52:** e83-e87.
[3]. Lance JW. Spasticity: Disordered Motor Control. *Year Book Medical Publishers*. Chicago, 1980: 485-495.
[4]. Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW. Classification and definition of disorders causing hypertonia in childhood. *Pediatrics*. 2003 **111:** e89-e97.
[5]. Lin JP. The contribution of spasticity to the movement disorder of cerebral palsy using pathway analysis: does spasticity matter? *Dev Med Child Neurol*. 2011 **53:** 7-9.
[6]. Malhotra S, Pandyan AD, Day CR, Jones PW, Hermens H. Spasticity, an impairment that is poorly defined and poorly measured. *Clin Rehabil*. 2009 **23:** 651-658.
[7]. Bar-On L, Molenaers G, Aertbelien E*, et al.* Spasticity and its contribution to hypertonia in cerebral palsy. *Biomed Res Int*. 2015 **2015:** 317047.
[8]. Burridge JH, Wood DE, Hermens HJ*, et al.* Theoretical and methodological considerations in the measurement of spasticity. *Disabil Rehabil*. 2005 **27:** 69-80.
[9]. Pandyan AD, Gregoric M, Barnes MP*, et al.* Spasticity: clinical perceptions, neurological realities and meaningful measurement. *Disabil Rehabil*. 2005 **27:** 2-6.
[10]. Lin JP. The assessment and management of hypertonus in cerebral palsy: a physiological atlas ('road map'). In: Scrutton D, Damiano D, Mayston M, eds. *Management of the Motor Disorders of Children with Cerebral Palsy Clinics in Developmental Medicine*. 2nd edn. London: Mac Keith Press, 2004: 85-104.
[11]. Graham HK, Rosenbaum P, Paneth N*, et al.* Cerebral palsy. *Nat Rev Dis Primers*. 2016 **2:** 15082.
[12]. Sheean G. Neurophysiology of spasticity. In: Barnes MP, Johnson GR, eds. *Upper Motor Neurone Syndrome and Spasticity Clinical Management and Neurophysiology*. 2nd edn. Cambridge: University Press, 2008: 9-63.
[13]. Peacock WJ. The pathophysiology of spasticity. In: Gage JR, Schwartz MH, Koop SE, Novacheck TF, eds. *The identification and treatment of gait problems in cerebral palsy*. 2nd edn. London: Mac Keith Press, 2009: 89-98.
[14]. Scholtes VA, Becher JG, Beelen A, Lankhorst GJ. Clinical assessment of spasticity in children with cerebral palsy: a critical review of available instruments. *Dev Med Child Neurol*. 2006 **48:** 64-73.
[15]. Scholtes VAB, Dallmeijer AJ, Becher JG. The Spasticity Test: a clinical instrument to measure spasticity in children with cerebral palsy. *The effectiveness of multilevel botulinum toxin type A and comprehensive rehabilitation in children with cerebral palsy*. Amsterdam, The Netherlands: VU University Medical Center, 2007: 29-64.
[16]. van den Noort JC, Scholtes VA, Harlaar J. Evaluation of clinical spasticity assessment in cerebral palsy using inertial sensors. *Gait Posture*. 2009 **30:** 138-143.
[17]. Bohannon RW, Smith MB. Interrater Reliability of A Modified Ashworth Scale of Muscle Spasticity. *Physical Therapy*. 1987 **67:** 206-207.
[18]. Patrick E, Ada L. The Tardieu Scale differentiates contracture from spasticity whereas the Ashworth Scale is confounded by it. *Clin Rehabil*. 2006 **20:** 173-182.

[19]. Haugh AB, Pandyan AD, Johnson GR. A systematic review of the Tardieu Scale for the measurement of spasticity. *Disabil Rehabil*. 2006 **28:** 899-907.
[20]. Tardieu G, SHENTOUB S, DELARUE R. Research on a technic for measurement of spasticity. *Rev Neurol (Paris)*. 1954 **91:** 143-144.
[21]. Fleuren JF, Voerman GE, Erren-Wolters CV*, et al.* Stop using the Ashworth Scale for the assessment of spasticity. *J Neurol Neurosurg Psychiatry*. 2010 **81:** 46-52.
[22]. Bar-On L, Aertbelien E, Molenaers G, Dan B, Desloovere K. Manually controlled instrumented spasticity assessments: a systematic review of psychometric properties. *Dev Med Child Neurol*. 2014 **56:** 932-950.
[23]. Platz T, Eickhof C, Nuyens G, Vuadens P. Clinical scales for the assessment of spasticity, associated phenomena, and function: a systematic review of the literature. *Disabil Rehabil*. 2005 **27:** 7-18.
[24]. Flamand VH, Masse-Alarie H, Schneider C. Psychometric evidence of spasticity measurement tools in cerebral palsy children and adolescents: a systematic review. *J Rehabil Med*. 2013 **45:** 14-23.
[25]. Johnson GR, Pandyan AD. The measurement of spasticity. In: Barnes MP, Johnson GR, eds. *Upper Motor Neurone Syndrome and Spasticity Clinical Management and Neurophysiology*. 2nd edn. Cambridge: University Press, 2008: 64-78.
[26]. van den Noort JC, Scholtes VA, Becher JG, Harlaar J. Evaluation of the catch in spasticity assessment in children with cerebral palsy. *Arch Phys Med Rehabil*. 2010 **91:** 615-623.
[27]. Bar-On L, Desloovere K, Molenaers G, Harlaar J, Kindt T, Aertbelien E. Identification of the neural component of torque during manually-applied spasticity assessments in children with cerebral palsy. *Gait Posture*. 2014 **40:** 346-351.
[28]. Bar-On L, Aertbelien E, Molenaers G*, et al.* Comprehensive quantification of the spastic catch in children with cerebral palsy. *Res Dev Disabil*. 2013 **34:** 386-396.
[29]. Bar-On L, Van CA, Desloovere K*, et al.* Is an instrumented spasticity assessment an improvement over clinical spasticity scales in assessing and predicting the response to integrated botulinum toxin type a treatment in children with cerebral palsy? *Arch Phys Med Rehabil*. 2014 **95:** 515-523.
[30]. Bar-On L, Aertbelien E, Wambacq H*, et al.* A clinical measurement to quantify spasticity in children with cerebral palsy by integration of multidimensional signals. *Gait Posture*. 2013 **38:** 141-147.
[31]. Palmieri RM, Ingersoll CD, Hoffman MA. The hoffmann reflex: methodologic considerations and applications for use in sports medicine and athletic training research. *J Athl Train*. 2004 **39:** 268-277.
[32]. Voerman GE, Gregoric M, Hermens HJ. Neurophysiological methods for the assessment of spasticity: the Hoffmann reflex, the tendon reflex, and the stretch reflex. *Disabil Rehabil*. 2005 **27:** 33-68.
[33]. Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. *PLoS One*. 2011 **6:** e20476.
[34]. Raghavendra P, Bornman J, Granlund M, Bjorck-Akesson E. The World Health Organization's International Classification of Functioning, Disability and Health: implications for clinical and research practice in the field of augmentative and alternative communication. *Augment Altern Commun*. 2007 **23:** 349-361.
[35]. Trost JP. Clinical assessment. In: Gage JR, Schwartz MH, Koop SE, Novacheck TF, eds. *The identification and treatment of gait problems in cerebral palsy*. 2nd edn. London: Mac Keith Press, 2009: 181-204.

[36]. Ada L, Bakheit AMO, Bardsley GI*, et al. Upper motor neurone syndrome and spasticity: clinical management and neurophysiology*. Cambridge, UK: Cambridge University Press, 2008.
[37]. Fleuren JF, Nederhand MJ, Hermens HJ. Influence of posture and muscle length on stretch reflex activity in poststroke patients with spasticity. *Arch Phys Med Rehabil*. 2006 **87:** 981-988.
[38]. Bar-On L, Aertbelien E, Molenaers G, Desloovere K. Muscle activation patterns when passively stretching spastic lower limb muscles of children with cerebral palsy. *PLoS One*. 2014 **9:** e91759.
[39]. Becher JG, Doorenbosch C, Folmer K, Scholtes V, Voorman J, Wolterbeek N. *Handleiding Standaard Lichamelijk Onderzoek bij kinderen met een Centraal Motorische Parese*. Amsterdam: Read Business BV, 2015.
[40]. Sloot LH, van der Krogt MM, KL dG-vdG*, et al.* The validity and reliability of modelled neural and tissue properties of the ankle muscles in children with cerebral palsy. *Gait Posture*. 2015 **42:** 7-15.
[41]. KL dG-vdG, de VE, de Groot JH*, et al.* Differentiation between non-neural and neural contributors to ankle joint stiffness in cerebral palsy. *J Neuroeng Rehabil*. 2013 **10:** 81.
[42]. de Vlugt E, Schouten AC, van der Helm FC. Quantification of intrinsic and reflexive properties during multijoint arm posture. *J Neurosci Methods*. 2006 **155:** 328-349.
[43]. de Vlugt E, de Groot JH, Schenkeveld KE, Arendzen JH, van der Helm FC, Meskers CG. The relation between neuromechanical parameters and Ashworth score in stroke patients. *J Neuroeng Rehabil*. 2010 **7:** 35.
[44]. Sloot LH, Bar-On L, van der Krogt MM*, et al.* Motorized versus manual instrumented spasticity assessment in children with cerebral palsy. *Developmental Medicine and Child Neurology*. 2017 **59:** 145-151.
[45]. Sloot LH, van den Noort JC, van der Krogt MM, Bruijn SM, Harlaar J. Can Treadmill Perturbations Evoke Stretch Reflexes in the Calf Muscles? *PLoS One*. 2015 **10:** e0144815.